BMRA vs. TRIB, CDIO, MYMD, OCX, NAVB, ICCC, AWH, COEP, CNTG, and PPBT
Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Trinity Biotech (TRIB), Cardio Diagnostics (CDIO), MyMD Pharmaceuticals (MYMD), OncoCyte (OCX), Navidea Biopharmaceuticals (NAVB), ImmuCell (ICCC), Aspira Women's Health (AWH), Coeptis Therapeutics (COEP), Centogene (CNTG), and Purple Biotech (PPBT). These companies are all part of the "medical" sector.
Trinity Biotech (NASDAQ:TRIB) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
Biomerica has lower revenue, but higher earnings than Trinity Biotech. Biomerica is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.
Trinity Biotech has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Biomerica has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500.
In the previous week, Trinity Biotech had 4 more articles in the media than Biomerica. MarketBeat recorded 6 mentions for Trinity Biotech and 2 mentions for Biomerica. Trinity Biotech's average media sentiment score of 0.34 beat Biomerica's score of 0.23 indicating that Biomerica is being referred to more favorably in the news media.
79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by company insiders. Comparatively, 13.5% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Trinity Biotech received 181 more outperform votes than Biomerica when rated by MarketBeat users. Likewise, 70.98% of users gave Trinity Biotech an outperform vote while only 67.82% of users gave Biomerica an outperform vote.
Trinity Biotech has a net margin of -42.26% compared to Trinity Biotech's net margin of -117.46%. Biomerica's return on equity of 0.00% beat Trinity Biotech's return on equity.
Summary
Trinity Biotech beats Biomerica on 10 of the 15 factors compared between the two stocks.
Get Biomerica News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomerica Competitors List
Related Companies and Tools
